Let you clearly know “how your immunity is right now” — no longer just a feeling
Many cancer patients, after treatment or during long-term follow-up, most often ask:
“Has my immunity recovered yet?”
Conventional blood tests showing white blood cell or lymphocyte counts can only tell you “normal” or “low”,
but cannot reveal the overall “fighting strength” of your immune system at this moment.
Clearing up doubts about circulating tumour cell (CTC) monitoring
RGCC cancer monitoring tests (OncoTrace, Onco-D-clare, Onconomics Plus®, etc.) have become valuable supportive tools for many patients during post-surgical follow-up, active treatment, or long-term surveillance.
In the field of modern oncology, early detection and personalized treatment have become key to improving survival rates and quality of life for patients. RGCC (Research Genetic Cancer Centre) testing is a series of advanced blood-based assays that require only a single blood draw to analyze circulating tumor cells (CTCs) and related biomarkers. These tests provide critical insights into the presence, progression, and treatment response of cancer, helping physicians create truly tailored treatment plans. The three most commonly used tests—Oncotrace, Onco-D-clare, and Onconomics Plus—excel in monitoring, screening, and treatment optimization, respectively.
A cancer diagnosis often brings immense physical and emotional burdens. Beyond the disease itself, treatments such as chemotherapy and radiotherapy frequently cause side effects including pain, fatigue, loss of appetite, nausea, sleep disturbances, and emotional distress. These symptoms not only affect quality of life but can also interfere with primary cancer treatments. Palliative Support Care is a patient-centered, comprehensive approach designed to intervene from the early stages of diagnosis, alleviating symptoms and improving overall well-being, enabling patients to maintain comfort, dignity, and autonomy throughout their treatment journey.
RGCC OncoTrace is one of the most advanced circulating tumour cell (CTC) detection and monitoring technologies available internationally. With a single blood draw, it can capture cancer cells that have “escaped” the tumour and are circulating in the blood, providing key information on quantity, phenotype, and activity. This allows physicians to detect changes before tumour markers rise or imaging shows any alteration.
Surgery is complete and the tumour has been removed —
many believe the hardest part is over.
But for most patients, the real challenge begins in the postoperative phase:
How to heal wounds faster? When will fatigue finally lift?
How to monitor recurrence risk? Can quality of life return to normal?
When cancer treatment — especially haematological malignancies, bone-marrow transplantation, long-term corticosteroids, or rituximab —
drives the immune system into “low-battery mode”,
the most common consequences are:
colds that drag on for weeks, recurrent pneumonia, shingles covering half the body, wounds that refuse to heal…
oral mucosa shredded, swallowing feels like broken glass, taste disappears, weight drops 1–2 kg per week…
The sentence we hear most often is:
“I know I need protein, but I physically can’t eat or swallow anything.”
Virtually every patient on androgen-deprivation therapy (ADT) faces progressive bone loss:
on average 4–7 % per year of treatment,
with fracture risk rising 2- to 5-fold within five years.
A single hip or vertebral fracture can dramatically affect quality of life and prognosis.
For patients on prolonged parenteral nutrition (TPN) — after pancreatic/gastric surgery, short-bowel syndrome, severe Crohn’s disease, or radiation enteritis —
zinc is one of the most easily overlooked yet critically important trace elements.
Only a few milligrams are needed daily, but zinc is involved in over 300 enzymes, wound healing, taste, immunity, and intestinal mucosal repair.
When it is lacking, the body falls into a vicious cycle: wounds won’t close, taste disappears, infections linger, and recovery stalls.